{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-080058","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2026-07-02T10:20:28+00:00","discovered_at":"2026-07-02T10:25:00.329006+00:00","generated_at":"2026-07-02T10:25:04.813703+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elicio Therapeutics prices $15M registered direct offering of 4.38M shares at $3.43/share","bullets":["Offering of 4,380,313 shares of common stock at $3.43 per share for gross proceeds of ~$15M.","Two new institutional investors and a large existing shareholder participated; expected close July 6, 2026.","Net proceeds to fund Phase 1 clinical development of ELI-002 7P in metastatic PDAC and pipeline/platform.","Titan Partners (lead) and B. Riley Securities (co-placement agent) acted as placement agents.","Offering made under effective shelf registration statement (File No. 333-293861)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-080058","json":"https://secwatch.observer/filing/0001104659-26-080058.json","markdown":"https://secwatch.observer/filing/0001104659-26-080058.md","text":"https://secwatch.observer/filing/0001104659-26-080058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000110465926080058/0001104659-26-080058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000110465926080058/tm2619637d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-02T10:25:04.813703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}